PDGFRA and gastrointestinal stromal tumor: Several studies have shown that response to imatinib in patients with GIST mainly depends on the mutational status of KIT or PDGFRA. Moreover, most if not all patients treated with imatinib for advanced GIST will secondarily develop progressive disease under treatment.